专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009002947A3 COMPOUNDS AND PEPTIDES THAT BIND THE TRAIL RECEPTOR 审中-公开
标题翻译：结合TRAIL受体的化合物和肽
公开(公告)号：WO2009002947A3
公开(公告)日：2009-04-02
申请号：PCT/US2008067941
申请日：2008-06-23
申请人： AFFYMAX INC , ANGELL YVONNE M , BHANDARI ASHOK , DE FRANCISCO NURIA M , FREDERICK BRIAN T , GREEN JENNIFER , LEU KAREN , LEUTHER KERSTIN , SANA REUBEN , WHITEHORN ERIK A , SCHATZ PETER J , HOLMES CHRISTOPHER P
发明人： ANGELL YVONNE M , BHANDARI ASHOK , DE FRANCISCO NURIA M , FREDERICK BRIAN T , GREEN JENNIFER , LEU KAREN , LEUTHER KERSTIN , SANA REUBEN , WHITEHORN ERIK A , SCHATZ PETER J , HOLMES CHRISTOPHER P
IPC分类号： C12Q1/68
CPC分类号： C07K14/70575 , A61K38/00 , C07K14/70578
摘要： The present invention relates to peptides and compounds that bind to a TRAIL receptor or otherwise act as a TRAIL receptor agonist, as well as methods of treating human diseases using the same. In addition, methods of synthesizing the peptides and compounds described herein are provided by the present invention.
摘要翻译：本发明涉及结合TRAIL受体或以其它方式作为TRAIL受体激动剂的肽和化合物，以及使用其治疗人类疾病的方法。此外，本发明提供了合成本文所述的肽和化合物的方法。

2. 发明申请

WO2003048302A3 IDENTIFYING ANTI-TUMOR TARGETS OR AGENTS BY LIPID RAFT IMMUNIZATION AND PROTEOMICS 审中-公开
公开(公告)号：WO2003048302A3
公开(公告)日：2003-06-12
申请号：PCT/US2002/032493
申请日：2002-10-10
申请人： PROTEIN DESIGN LABS INC. , TSO, Yun, J. , MCPHATE GREEN, Jennifer
发明人： TSO, Yun, J. , MCPHATE GREEN, Jennifer
IPC分类号： G01N33/53
摘要： The present invention is directed to a method for identifying anti-tumor targets by examining lipid rafts. It provides for a method for identifying anti-tumor targets by lipid raft proteomics and a method for identifying anti-tumor agents by lipid rafts immunization. It also provides for hybridomas produced by the method of identifying anti-tumor agents by lipid raft immunization, and antibodies produced by the hybridomas. It also provides for the anti-tumor targets or agents identified by the methods in the present invention.

3. 发明申请

WO2003048301A3 ANTI-HLA-DR ANTIBODIES AND THE METHODS OF USING THEREOF 审中-公开
公开(公告)号：WO2003048301A3
公开(公告)日：2003-06-12
申请号：PCT/US2002/032491
申请日：2002-10-10
申请人： PROTEIN DESIGN LABS INC. , TSO, Yun, J. , MCPHATE GREEN, Jennifer
发明人： TSO, Yun, J. , MCPHATE GREEN, Jennifer
IPC分类号： A61K39/395
摘要： This invention provides anti-HLA-DR antibodies and the methods of use thereof for the treatment of leukemia or lymphomas, or solid tumors such as ovarian cancer or melanoma.

4. 发明申请

WO2002096886A1 PYRIMIDINE DERIVATIVES 审中-公开
标题翻译：吡嗪衍生物
公开(公告)号：WO2002096886A1
公开(公告)日：2002-12-05
申请号：PCT/GB2002/002408
申请日：2002-05-23
申请人： GLAXO GROUP LIMITED , GREEN, Jennifer Margaret , BRAVI, Gianpaolo , CARTER, Malcolm , HARTLEY, Charles, David , NAYLOR, Alan , PASS, Martin , PAYNE, Jeremy, John , PEGG, Neil, Anthony
发明人： BRAVI, Gianpaolo , CARTER, Malcolm , HARTLEY, Charles, David , NAYLOR, Alan , PASS, Martin , PAYNE, Jeremy, John , PEGG, Neil, Anthony
IPC分类号： C07D239/42
CPC分类号： C07D239/42 , C07D401/12 , C07D405/12 , C07D409/12
摘要： The invention provides the compounds of formula (I) and pharmaceutically acceptable salts thereof, in which: R 1 and R 2 are independently selected from the group consisting of H, C 1-6 alkyl, C 1-2 alkyl substituted by one to five fluorine atoms, C 3-6 alkenyl, C 3-6 alkynyl, C 3 -cycloalkylC 0-6 alkyl, C 4-12 bridged cycloalkyl, A(CR 7 R 8 ) n and B(CR 7 R 8 ) n ; R 3 is selected from the group consisting of C 1-6 alkyl, NH 2 and R 10 CONH; R 4 is C 1-2 alkyl substituted by one to five fluorine atoms; R 5 is selected from the group consisting of H, C 1-4 alkyl, C 1-2 alkyl substituted with one to five fluorine atoms, halogen and C 3-10 cycloalkylC 0-6 alkyl, with the proviso that when R 6 is H R 5 is not H. R 6 is selected from the group consisting of H, C 1-4 alkyl, C 1-2 alkyl substituted with one to five fluorine atoms, halogen, C 1-4 alkoxy, CN, NO 2 , C 1-6 alkylOCO, NH 2 CO C 1-6 alkylNHCO, NH 2 , C 1-6 alkylNH, (C 1-6 alkyl) 2 N, (C 1-6 alkyl) 2 NCO, C 1-6 alkylCONH, NH 2 SO 2 , C 1-6 alkylNHSO 2 (C 1-6 alkyl) 2 NSO 2 , C 1-6 alkylSO 2 NH, ArSO 2 NH, C 1-6 alkylSO 2 , ArSO 2 , C 3-10cycloalkylC¿0-6 alkyl, C 3-6 alkenyl and C 3-6 alkynyl, with the proviso that when R 5 is H R 6 is not H. R 7 and R 8 are independently selected from H or C 1-6 alkyl; A is an unsubstituted 5- or 6-membered heteroaryl or an unsubstituted 6-membered aryl, or a 5- or 6-membered heteroaryl or a 6-membered aryl substituted by one or more R 9 is selected from the group consisting of hydroxy, halogen, C 1-6 alkyl, C 1-6 alkyl substituted by one mor fluorine atoms, C 1-6 alkoxy, C 1-6 alkoxy substituted by one or more F, NH 2 SO 2 and C 1-6 alkylSO 2 ; R 10 is selected from the group consisting of H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylOC 1-6 alkyl, phenyl, HO 2 CC 1-6 alkyl, C 1-6 alkylOCOC 1-6 alkyl, C 1-6 alkylOCO, H 2 NC 1-6 alkyl, C 1-6 alkylOCONHC 1-6 alkyl and C 1-6 alkylCONHC 1-6 alkyl; B is selected from the group consisting of (II) and where (III) defines the point of attachmnent of the ring; and n is 0 to 4. Compounds of formula (I) are potent and selective inhibitors of COX-2 and are of use in the treatment of pain, fever and inflammation of a variety of conditions and diseases.
摘要翻译：本发明提供式（I）化合物及其药学上可接受的盐，其中：R 1和R 2独立地选自H，C 1-6烷基，被1至5个取代的C 1-2烷基氟原子，C 3-6烯基，C 3-6炔基，C 3-环烷基C 1-6烷基，C 4-12桥环烷基，A（CR 7 R 8）n和B（CR 7 R 8）n; R 3选自C 1-6烷基，NH 2和R 10 CONH; R 4是被1至5个氟原子取代的C 1-2烷基; R 5选自H，C 1-4烷基，被1至5个氟原子取代的C 1-2烷基，卤素和C 3-10环烷基C 1-6烷基，条件是当R 6为HR 5时，不是H.R 6选自H，C 1-4烷基，被1至5个氟原子取代的C 1-2烷基，卤素，C 1-4烷氧基，CN，NO 2，C 1-6烷基COO，NH 2 CO C 1-6烷基NHCO ，C 1-6烷基NH，（C 1-6烷基）2 N，（C 1-6烷基）2 CO，C 1-6烷基CONH，NH 2 SO 2，C 1-6烷基NHSO 2（C 1-6烷基）2 NSO 2，C 1-6烷基SO 2 NH，ArSO 2 NH，C 1-6烷基SO 2，ArSO 2， -10个环烷基C 0-6烷基，C 3-6烯基和C 3-6炔基，条件是当R 5是HR 6不是H. R 7和R 8独立地选自H或C 1-6烷基; A是未取代的5-或6-元杂芳基或未取代的6-元芳基，或被一个或多个R 9取代的5-或6-元杂芳基或6-元芳基选自羟基，卤素，C 1-6烷基，被一个氟原子取代的C 1-6烷基，C 1-6烷氧基，被一个或多个F，NH 2 SO 2和C 1-6烷基SO 2取代的C 1-6烷氧基; R 10选自H，C 1-6烷基，C 1-6烷氧基，C 1-6烷基C 1-6烷基，苯基，HO 2 CCl 1-6烷基，C 1-6烷基COC 1-6烷基，C 1-6烷基COO，H 2 NC 1-6烷基，C 1-6烷基OCONHC 1 -6-烷基和C 1-6烷基CONHC 1-6烷基; B选自（II），其中（III）定义环的附着点; 并且n为0至4.式（I）化合物是COX-2的有效和选择性抑制剂，并且可用于治疗各种病症和疾病的疼痛，发热和炎症。

5. 发明申请

WO2009002947A2 COMPOUNDS AND PEPTIDES THAT BIND THE TRAIL RECEPTOR 审中-公开
标题翻译：结合TRAIL受体的化合物和肽
公开(公告)号：WO2009002947A2
公开(公告)日：2008-12-31
申请号：PCT/US2008/067941
申请日：2008-06-23
申请人： AFFYMAX, INC. , ANGELL, Yvonne, M. , BHANDARI, Ashok , DE FRANCISCO, Nuria, M. , FREDERICK, Brian, T. , GREEN, Jennifer , LEU, Karen , LEUTHER, Kerstin , SANA, Reuben , WHITEHORN, Erik, A. , SCHATZ, Peter, J. , HOLMES, Christopher, P.
发明人： ANGELL, Yvonne, M. , BHANDARI, Ashok , DE FRANCISCO, Nuria, M. , FREDERICK, Brian, T. , GREEN, Jennifer , LEU, Karen , LEUTHER, Kerstin , SANA, Reuben , WHITEHORN, Erik, A. , SCHATZ, Peter, J. , HOLMES, Christopher, P.
IPC分类号： A61K38/10
CPC分类号： C07K14/70575 , A61K38/00 , C07K14/70578
摘要： The present invention relates to peptides and compounds that bind to a TRAIL receptor or otherwise act as a TRAIL receptor agonist, as well as methods of treating human diseases using the same. In addition, methods of synthesizing the peptides and compounds described herein are provided by the present invention.
摘要翻译：本发明涉及结合TRAIL受体或以其它方式作为TRAIL受体激动剂的肽和化合物，以及使用其治疗人类疾病的方法。此外，本发明提供了合成本文所述的肽和化合物的方法。

6. 发明申请

WO2006074066A1 NON-CRYSTALLINE FORMULATION COMPRISING CLOPIDOGREL 审中-公开
标题翻译：包含CLOPIDOGREL的非晶体配方
公开(公告)号：WO2006074066A1
公开(公告)日：2006-07-13
申请号：PCT/US2005/047424
申请日：2005-12-29
申请人： NEKTAR THERAPEUTICS , GREEN, Jennifer, Anne , DAINTREE, Linda, Sharon , KORDIKOWSKI, Andreas , DUDDU, Sarma , ZHANG, Jiang , PALAKODATY, Srinivas , TONG, Maurine
发明人： GREEN, Jennifer, Anne , DAINTREE, Linda, Sharon , KORDIKOWSKI, Andreas , DUDDU, Sarma , ZHANG, Jiang , PALAKODATY, Srinivas , TONG, Maurine
IPC分类号： A61K31/4365 , C07D495/04 , C08G65/333
CPC分类号： C08J3/14 , A61K31/4365 , C07D495/04 , C08J3/215
摘要： One or more embodiments of the invention provide various novel formulation, and tablet dosage forms, comprising clopidogrel, and particles comprising clopidogrel, that are non-crystalline, stable flowable, non-sticky and/or otherwise improvements over known clopidogrel formulations. One or more embodiments of the invention further provide methods for preparing the formulation, methods for preparing the tablet dosage form, and to methods, of administering the tablet dosage and/or formulation comprising clopidogrel. The clopidogrel-containing formulations may be administered to a user to treat platelet aggregation and/or thrombosis, and related conditions.
摘要翻译：本发明的一个或多个实施方案提供了各种新颖的制剂和片剂剂型，其包含氯吡格雷和包含氯吡格雷的颗粒，其是非已知氯吡格雷制剂的非结晶，稳定的可流动，不粘和/或以其它方式改进的。本发明的一个或多个实施方案还提供了制备制剂的方法，制备片剂剂型的方法，以及施用包含氯吡格雷的片剂剂量和/或制剂的方法。含氯吡格雷的制剂可以施用于使用者以治疗血小板聚集和/或血栓形成以及相关条件。

7. 发明申请

WO2003030831A2 TREATMENT OF PROSTATE CANCER BY INHIBITORS OF ATP SYNTHASE 审中-公开
标题翻译： ATP合成酶抑制剂治疗前列腺癌的治疗
公开(公告)号：WO2003030831A2
公开(公告)日：2003-04-17
申请号：PCT/US2002/032494
申请日：2002-10-10
申请人： PROTEIN DESIGN LABS, INC. , TSO, J. Yun, , MCPHATE GREEN, Jennifer
发明人： TSO, J. Yun, , MCPHATE GREEN, Jennifer
IPC分类号： A61K
CPC分类号： G01N33/57492 , A61K2039/505 , C07K16/2833 , C07K16/30 , C07K16/3015 , C07K16/3069 , C07K16/40 , C07K2317/73 , G01N2405/00
摘要： The present invention is directed to a method of treating or preventing prostate cancer in a subject in need of such a treatment by administering an inhibitor of ATP synthase activity in a pharmaceutically effective amount. The present invention also provides for a pharmaceutical composition comprising an inhibitor of ATP synthase.
摘要翻译：本发明涉及通过以药学有效量施用ATP合酶活性抑制剂来治疗或预防需要这种治疗的受试者的前列腺癌的方法。本发明还提供了包含ATP合酶抑制剂的药物组合物。

8. 发明申请

WO02096886A8 PYRIMIDINE DERIVATIVES 审中-公开
标题翻译：吡嗪衍生物
公开(公告)号：WO02096886A8
公开(公告)日：2004-07-22
申请号：PCT/GB0202408
申请日：2002-05-23
申请人： GLAXO GROUP LTD , BRAVI GIANPAOLO , CARTER MALCOLM , GREEN JENNIFER MARGARET HF , HARTLEY CHARLES DAVID , NAYLOR ALAN , PASS MARTIN , PAYNE JEREMY JOHN , PEGG NEIL ANTHONY
发明人： BRAVI GIANPAOLO , CARTER MALCOLM , GREEN RICHARD HOWARD DI , HARTLEY CHARLES DAVID , NAYLOR ALAN , PASS MARTIN , PAYNE JEREMY JOHN , PEGG NEIL ANTHONY
IPC分类号： A61K31/505 , A61K31/506 , A61P29/00 , A61P43/00 , C07D239/42 , C07D401/12 , C07D405/12 , C07D409/12
CPC分类号： C07D239/42 , C07D401/12 , C07D405/12 , C07D409/12
摘要： The invention provides the compounds of formula (I) and pharmaceutically acceptable salts thereof, in which: R
摘要翻译：本发明提供式（I）化合物及其药学上可接受的盐，其中：R 1和R 2独立地选自H，C 1-6烷基，C 1-6烷基， 2个被1至5个氟原子取代的烷基，C 3-6烯基，C 3-6炔基，C 3〜8环烷基C 1-6烷基，C 1-4-12桥连环烷基，A （CR？7¿R？8¿）¿N + 和B（CR？7？R？8）？ R 3选自C 1-6烷基，NH 2，和R 10〜CONH; R 4是被1至5个氟原子取代的C 1-22烷基; R 5选自H，C 1-4 - 烷基，被1至5个氟原子取代的C 1-2-2烷基，卤素和C 1-3-10环烷基C 0〜 6烷基，条件是当R 6为HR 5时，不是H.R 6选自H，C 1-4烷基，C 1-12烷基被一至五个氟原子取代，卤素，C 1-4烷氧基，CN，NO 2，C 1-6烷基COO，NH 2，CO C 1-6烷基NHCO，NH 2，，C 1-6烷基NH，（C 1-6烷基）2 N，（C 1-6烷基）2 NCO，C 1-6烷基CONH，NH 2 SO 2，C 1-6烷基NHSO 2 （C 1-6烷基）≡2NOSO2，C 1-6烷基SO 2 NH，ArSO 2 NH，C 1-6烷基SO 2，ArSO 2， C 3-6环烷基C 1-6烷基，C 3-6烯基和C 3-6链炔基，条件是当R 5为HR 6时，不是H. 7和R 8独立地选自H或C 1-6烷基; A是未取代的5-或6-元杂芳基或未取代的6-元芳基，或被一个或多个R 9取代的5-或6-元杂芳基或6-元芳基选自羟基，卤素，C 1-6烷基，被一个氟原子取代的C 1-6烷基，C 1-6烷氧基，被一个或多个F，NH取代的C 1-6烷氧基， 2？SO¿2？和C 1-6烷基SO 2 R 10选自H，C 1-6 - 烷基，C 1-6烷氧基，C 1-6烷基OC 1-6 - 烷基，苯基，HO 2 C C 1-6烷基，C 1-6烷基COOC 1-6烷基，C 1-6烷基COO，C 1-6烷基，C 1-6烷基OCONHC -6 - 烷基和C 1-6烷基CONHC 1-6 - 烷基; B选自（II）和（III），其中（IV）定义环的附着点; 并且n为0至4.式（I）化合物是COX-2的有效和选择性抑制剂，并且可用于治疗各种病症和疾病的疼痛，发烧和炎症。

9. 发明申请

WO2003048302A2 IDENTIFYING ANTI-TUMOR TARGETS OR AGENTS BY LIPID RAFT IMMUNIZATION AND PROTEOMICS 审中-公开
标题翻译：通过脂肪细胞免疫和保护来鉴定抗肿瘤靶标或代理
公开(公告)号：WO2003048302A2
公开(公告)日：2003-06-12
申请号：PCT/US2002/032493
申请日：2002-10-10
申请人： PROTEIN DESIGN LABS INC. , TSO, Yun, J. , MCPHATE GREEN, Jennifer
发明人： TSO, Yun, J. , MCPHATE GREEN, Jennifer
IPC分类号： C12N
CPC分类号： G01N33/57492 , A61K2039/505 , C07K16/2833 , C07K16/30 , C07K16/3015 , C07K16/3069 , C07K16/40 , C07K2317/73 , G01N2405/00
摘要： The present invention is directed to a method for identifying anti-tumor targets by examining lipid rafts. It provides for a method for identifying anti-tumor targets by lipid raft proteomics and a method for identifying anti-tumor agents by lipid rafts immunization. It also provides for hybridomas produced by the method of identifying anti-tumor agents by lipid raft immunization, and antibodies produced by the hybridomas. It also provides for the anti-tumor targets or agents identified by the methods in the present invention.
摘要翻译：本发明涉及通过检查脂筏来鉴定抗肿瘤靶标的方法。它提供了通过脂筏蛋白质组学鉴定抗肿瘤靶标的方法以及通过脂筏免疫来鉴定抗肿瘤剂的方法。它还提供了通过脂质筏免疫鉴定抗肿瘤剂的方法产生的杂交瘤和由杂交瘤产生的抗体。它还提供了通过本发明的方法鉴定的抗肿瘤靶标或药剂。

10. 发明申请

WO2003048301A2 ANTI-HLA-DR ANTIBODIES AND THE METHODS OF USING THEREOF 审中-公开
标题翻译：抗HLA-DR抗体及其使用方法
公开(公告)号：WO2003048301A2
公开(公告)日：2003-06-12
申请号：PCT/US2002/032491
申请日：2002-10-10
申请人： PROTEIN DESIGN LABS INC. , TSO, Yun, J. , MCPHATE GREEN, Jennifer
发明人： TSO, Yun, J. , MCPHATE GREEN, Jennifer
IPC分类号： C12N
CPC分类号： G01N33/57492 , A61K2039/505 , C07K16/2833 , C07K16/30 , C07K16/3015 , C07K16/3069 , C07K16/40 , C07K2317/73 , G01N2405/00
摘要： This invention provides anti-HLA-DR antibodies and the methods of use thereof for the treatment of leukemia or lymphomas, or solid tumors such as ovarian cancer or melanoma.
摘要翻译：本发明提供抗HLA-DR抗体及其用于治疗白血病或淋巴瘤或实体瘤如卵巢癌或黑素瘤的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式